OR11-4 Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials

BACKGROUND: Thyroid eye disease (TED) can result in eye-bulging (proptosis) and double-vision (diplopia) and inflammation, which frequently impacts quality of life (QoL). Teprotumumab, an insulin like growth factor-1 receptor inhibitory antibody, improves TED outcomes and QoL(1) as measured by the G...

Descripción completa

Detalles Bibliográficos
Autores principales: Douglas, Raymond S, Holt, Robert, Qashqai, Anahita, Sile, Saba, Smith, Terry J, Vesel, Claudia, Kahaly, George J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627596/
http://dx.doi.org/10.1210/jendso/bvac150.1654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627596/
http://dx.doi.org/10.1210/jendso/bvac150.1654

Ejemplares similares